Bentonville, Ark.-based SymBiosis Capital Management, LLC has launched as a newly independent venture capital firm focused on advancing biotherapeutics innovations.
Investing since 2019, SymBiosis has received long-term capital commitments to actively support its current portfolio of more than 20 investments and fund future investments.
Led by Chidozie Ugwumba, Managing Partner, SymBiosis’s team will continue to target opportunities across disease area, financing stage, and geography, with a focus on private companies with programs in, or about to enter, human trials. The firm expects to initially deploy $5-$15m per investment, with the ability to scale up to over $30m per investment across multiple financings. The firm will continue to serve as both a lead and syndicate participant in financing rounds.
The team includes:
- Chidozie Ugwumba, Managing Partner: Mr. Ugwumba leads sourcing, due diligence and execution of investments, and serves as an advisor to SymBiosis’ portfolio companies. Prior to SymBiosis, he was Managing Director, Direct Investments at WIT, LLC.
- Aleksei Cremo, Vice President: Mr. Cremo helps to manage sourcing, due diligence and execution of investments, and serves as an advisor to SymBiosis’ portfolio companies. Prior to SymBiosis, he was an Associate focused on direct venture capital investments at WIT, LLC.
- Nick Smith, Investment Associate: Mr. Smith supports sourcing, due diligence, and other investment activities. Prior to SymBiosis, he was a Senior Analyst focused on direct venture capital investments at WIT, LLC.
- Molly Connor, Chief of Staff: Ms. Connor manages organizational and operational initiatives. Prior to SymBiosis, she was a Coordinator at WIT, LLC.
FinSMEs
27/10/2021